Literature DB >> 22101270

Mechanism of action of the multikinase inhibitor Foretinib.

Maeva Dufies1, Arnaud Jacquel, Guillaume Robert, Thomas Cluzeau, Alexandre Puissant, Nina Fenouille, Laurence Legros, Sophie Raynaud, Jill-Patrice Cassuto, Fréderic Luciano, Patrick Auberger.   

Abstract

Mitotic catastrophe (MC) is induced when stressed cells enter prematurely or inappropriately into mitosis and can be caused by ionizing radiation and anticancer drugs. Foretinib is a multikinase inhibitor whose mechanism of action is incompletely understood. We investigated here the effect of Foretinib on chronic myelogenous leukemia (CML) cell lines either sensitive (IM-S) or resistant (IM-R) to the tyrosine kinase inhibitor Imatinib. Foretinib decreased viability and clonogenic potential of IM-S and IM-R CML cells as well. Foretinib-treated cells exhibited increased size, spindle assembly checkpoint anomalies and enhanced ploidy that collectively evoked mitotic catastrophe (MC). Accordingly, Foretinib-stimulated CML cells displayed decreased expression of Cdk1, Cyclin B1 and Plk1. In addition, Foretinib triggered caspase-2 activation that precedes mitochondrial membrane permeabilization. Accordingly, z-VAD-fmk and a caspase-2 siRNA abolished Foretinib-mediated cell death but failed to affect MC, indicating that Foretinib-mediated apoptosis and MC are two independent events. Anisomycin, a JNK activator, impaired Foretinib-induced MC and inhibition or knockdown of JNK phenotyped its effect on MC. Moreover, we found that Foretinib acted as a potent inhibitor of JNK. Importantly, Foretinib exhibited no or very little effect on normal peripheral blood mononuclear cells, monocytes or melanocytes cells but efficiently inhibited the clonogenic potential of CD34+ cell from CML patients. Collectively, our data show that the multikinase inhibitor Foretinib induces MC in CML cells and other cell lines via JNK-dependent inhibition of Plk1 expression and triggered apoptosis by a caspase 2-mediated mechanism. This unusual mechanism of action may have important implications for the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22101270     DOI: 10.4161/cc.10.23.18323

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  15 in total

1.  Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution.

Authors:  Boyang Zhao; Joseph C Sedlak; Raja Srinivas; Pau Creixell; Justin R Pritchard; Bruce Tidor; Douglas A Lauffenburger; Michael T Hemann
Journal:  Cell       Date:  2016-02-25       Impact factor: 41.582

Review 2.  Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.

Authors:  Beatrix Wulkersdorfer; Markus Zeitlinger; Monika Schmid
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

3.  Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias.

Authors:  Bruno A Lopes; Caroline Pires Poubel; Cristiane Esteves Teixeira; Aurélie Caye-Eude; Hélène Cavé; Claus Meyer; Rolf Marschalek; Mariana Boroni; Mariana Emerenciano
Journal:  Front Pharmacol       Date:  2022-06-06       Impact factor: 5.988

4.  Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.

Authors:  Hsiu-Mei Chen; Chia-Hua Tsai; Wen-Chun Hung
Journal:  Oncotarget       Date:  2015-06-20

5.  CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia.

Authors:  Borja Guerra; Patricia Martín-Rodríguez; Juan Carlos Díaz-Chico; Grant McNaughton-Smith; Sandra Jiménez-Alonso; Idaira Hueso-Falcón; Juan Carlos Montero; Rosa Blanco; Javier León; Germán Rodríguez-González; Ana Estévez-Braun; Atanasio Pandiella; Bonifacio Nicolás Díaz-Chico; Leandro Fernández-Pérez
Journal:  Oncotarget       Date:  2017-05-02

6.  Foretinib Enhances the Radiosensitivity in Esophageal Squamous Cell Carcinoma by Inhibiting Phosphorylation of c-Met.

Authors:  Guang-Zong Chen; Wang-Shu Dai; Hong-Cheng Zhu; Hong-Mei Song; Xi Yang; Yuan-Dong Wang; Hua Min; Qian Lu; Shu Liu; Xin-Chen Sun; Xiao-Ning Zeng
Journal:  J Cancer       Date:  2017-03-12       Impact factor: 4.207

7.  E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

Authors:  Ilirjana Bajrami; Rebecca Marlow; Marieke van de Ven; Rachel Brough; Helen N Pemberton; Jessica Frankum; Feifei Song; Rumana Rafiq; Asha Konde; Dragomir B Krastev; Malini Menon; James Campbell; Aditi Gulati; Rahul Kumar; Stephen J Pettitt; Mark D Gurden; Marta Llorca Cardenosa; Irene Chong; Patrycja Gazinska; Fredrik Wallberg; Elinor J Sawyer; Lesley-Ann Martin; Mitch Dowsett; Spiros Linardopoulos; Rachael Natrajan; Colm J Ryan; Patrick W B Derksen; Jos Jonkers; Andrew N J Tutt; Alan Ashworth; Christopher J Lord
Journal:  Cancer Discov       Date:  2018-04       Impact factor: 39.397

8.  Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.

Authors:  Daniela Bressanin; Camilla Evangelisti; Francesca Ricci; Giovanna Tabellini; Francesca Chiarini; Pier Luigi Tazzari; Fraia Melchionda; Francesca Buontempo; Pasqualepaolo Pagliaro; Andrea Pession; James A McCubrey; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-08

9.  Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines.

Authors:  Thomas Cluzeau; Alix Dubois; Arnaud Jacquel; Frederic Luciano; Aline Renneville; Claude Preudhomme; Jean Michel Karsenti; Nicolas Mounier; Pierre Rohrlich; Sophie Raynaud; Bernard Mari; Guillaume Robert; Patrick Auberger
Journal:  Oncotarget       Date:  2014-06-30

10.  ATP-competitive Plk1 inhibitors induce caspase 3-mediated Plk1 cleavage and activation in hematopoietic cell lines.

Authors:  Maeva Dufies; Damien Ambrosetti; Sonia Boulakirba; Anne Calleja; Coline Savy; Nathan Furstoss; Marwa Zerhouni; Julien Parola; Lazaro Aira-Diaz; Sandrine Marchetti; Francois Orange; Sandra Lacas-Gervais; Frederic Luciano; Arnaud Jacquel; Guillaume Robert; Gilles Pagès; Patrick Auberger
Journal:  Oncotarget       Date:  2017-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.